Recognizing the critical role that emerging biopharmaceutical companies
play in the global marketplace, Quintiles today expanded its solution
set with the launch of the Quintiles
Emerging Biopharma Solution – a new offering designed to meet the
unique clinical development needs and goals of these companies.
BOTHELL, Wash., July 29, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. ("Alder") (Nasdaq:ALDR) , a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, today announced that it will report its second quarter 2014 financial and operating results after the close of U.S. financial markets on Tuesday, August 5, 2014.
Sign-up for Data From Alder BioPharmaceuticals' Proof-of-Concept Clinical Trial of ALD403 Published in Lancet Neurology Demonstrates ALD403 Effective in the Preventive Treatment of Migraine investment picks
CALABASAS, Calif., July 10, 2014 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that its New Drug Application (NDA) for ATX-101 (deoxycholic acid), has been accepted for filing by the U.S. Food and Drug Administration (FDA). The acceptance of the NDA reflects the FDA's determination that the application is sufficiently complete to permit a substantive review.
WESTLAKE VILLAGE, Calif., July 31, 2014 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it will release its second quarter 2014 operating results and will host an investor call and webcast at 4:30 p.m. ET on Thursday, August 7, 2014.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.